First Manhattan
SGMO

First Manhattan’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

First Manhattan’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,000
Closed -$26K – 1444
2020
Q2 		$26K Hold
3,000
– – ﹤0.01% 986
2020
Q1 		$19K Hold
3,000
– – ﹤0.01% 1010
2019
Q4 		$25K Hold
3,000
– – ﹤0.01% 1004
2019
Q3 		$27K Hold
3,000
– – ﹤0.01% 1001
2019
Q2 		$32K Buy
+3,000
New +$31.9K ﹤0.01% 1000

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan's SGMO Position: Q3 2020 in Review

First Manhattan sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2020, closing a stake of 3,000 shares — an estimated $26K sold.

First Manhattan first reported a position in SGMO in Q2 2019 and held it in 5 quarters. The position peaked at $32K in Q2 2019. 210 funds tracked by Wall St. Rank hold SGMO as of Q3 2020.

  • First Manhattan reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2020 after selling out during the quarter.
  • First Manhattan sold 3,000 SANGAMO THERAPEUTICS INC shares in Q3 2020, an estimated $26K.
  • First Manhattan first reported a position in SANGAMO THERAPEUTICS INC in Q2 2019 and held it in 5 quarters.
  • First Manhattan's SANGAMO THERAPEUTICS INC position peaked at $32K in Q2 2019.
  • 210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2020.

Based on First Manhattan's 13F filing for Q3 2020, filed 12 Nov 2020.